INSITE VISION ANNOUNCES POSITIVE RESULTS AZASITE TRIAL

A A

InSite Vision has announced positive top-line results from a pivotal Phase III clinical trial of AzaSite, a sterile, topical ophthalmic anti-infective solution containing 1 percent azithromycin.

In an international, controlled clinical trial, subjects with bacterial conjunctivitis (pink-eye) were treated with either AzaSite dosed twice a day for the first two days, followed by once a day for the next three days or 0.3 prcent tobramycin dosed four times a day for 5 days. AzaSite demonstrated a clinical resolution rate of 80 percent as compared to 78 percent for tobramycin. This result shows that the clinical resolution rate of AzaSite is equivalent to tobramycin, the primary efficacy endpoint of the study.